Literature DB >> 11340750

Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.

E Kozer1, M E Moretti, G Koren.   

Abstract

QUESTION: I am treating a 34-year-old woman with rheumatoid arthritis. She began taking the new drug leflunomide (Arava) 6 months ago and had good clinical response. She is now planning her first pregnancy. What should she do? ANSWER: Leflunomide is a new and effective disease-modifying antirheumatic drug. Animal studies have shown an increased rate of malformations and fetal death in various species, but there are no data on pregnancy outcomes in humans treated with leflunomide. Since the drug has a prolonged and unpredictable elimination half-life, it should be stopped during pregnancy. The manufacturer recommends that patients who wish to become pregnant be treated with cholestyramine, which enhances elimination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340750      PMCID: PMC2018413     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  15 in total

Review 1.  Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.

Authors:  R R Bartlett; S Brendel; T Zielinski; H U Schorlemmer
Journal:  Transplant Proc       Date:  1996-12       Impact factor: 1.066

2.  Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

Authors:  V Strand; S Cohen; M Schiff; A Weaver; R Fleischmann; G Cannon; R Fox; L Moreland; N Olsen; D Furst; J Caldwell; J Kaine; J Sharp; F Hurley; I Loew-Friedrich
Journal:  Arch Intern Med       Date:  1999-11-22

3.  Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.

Authors:  P J Mroczkowski; M E Weinblatt; J M Kremer
Journal:  Clin Exp Rheumatol       Date:  1999 Nov-Dec       Impact factor: 4.473

4.  A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Authors:  P Emery; F C Breedveld; E M Lemmel; J P Kaltwasser; P T Dawes; B Gömör; F Van Den Bosch; D Nordström; O Bjorneboe; R Dahl; K Horslev-Petersen; A Rodriguez De La Serna; M Molloy; M Tikly; C Oed; R Rosenburg; I Loew-Friedrich
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

5.  Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.

Authors:  J T Sharp; V Strand; H Leung; F Hurley; I Loew-Friedrich
Journal:  Arthritis Rheum       Date:  2000-03

Review 6.  Mechanism of action for leflunomide in rheumatoid arthritis.

Authors:  R I Fox; M L Herrmann; C G Frangou; G M Wahl; R E Morris; V Strand; B J Kirschbaum
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

7.  Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

Authors:  S K Manna; B B Aggarwal
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat.

Authors:  L S Yeh; C R Gregory; S M Griffey; R A Lecouteur; R E Morris
Journal:  Transplantation       Date:  1996-09-27       Impact factor: 4.939

9.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.

Authors:  J Jöckel; B Wendt; M Löffler
Journal:  Biochem Pharmacol       Date:  1998-10-15       Impact factor: 5.858

View more
  1 in total

1.  Chronic Diarrhea Associated with High Teriflunomide Blood Concentration.

Authors:  André Duquette; Anne Julie Frenette; Maxime Doré
Journal:  Rheumatol Ther       Date:  2016-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.